PolyPid Competitors and Similar CompaniesClear all
PolyPid's competitors and similar companies include Metabolon, Adaptimmune, VBI Vaccines and Meissa Vaccines.
 PolyPid PolyPid is a company developing a technology platform that enables a controlled and prolonged release of active pharmaceutical ingredients (API). |  Metabolon Global leader in metabolomics for precision medicine, biomarker discovery, and advancing pharma & life sciences research. |  Adaptimmune Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. |  VBI Vaccines VBI Vaccines is a biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. |  Meissa Vaccines Meissa Vaccines is a pharmaceutical company focused on the advancement of unmet vaccines against viruses that cause serious human diseases, such as a respiratory syncytial virus. | |
Founding Date | Founding Date 2008 | Founding Date 2000 | Founding Date 2008 | Founding Date 2001 | Founding Date 2014 |
Type | Type Public | Type Private | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Petah Tikva, IL HQ Summit, US | Locations Morrisville, US HQ Hallbergmoos, DE München, DE | Locations Philadelphia, US HQ Milton, GB Milton, GB Stevenage, GB | Locations Cambridge, US HQ Ottawa, CA Rehovot, IL | Locations South San Francisco, US HQ Redwood City, US |
Employees | Employees 57 | Employees 1911% increase | Employees 4007% decrease | Employees 12314% increase | Employees 3 |
Valuation ($) | Valuation ($) 23.7 m | Valuation ($) N/A | Valuation ($) 188.5 m | Valuation ($) 1.9 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $178m (FY, 2024) | Revenue (est.) $8.7m (FY, 2023) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $70k (FY, 2024) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $178m (FY, 2024) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($34.2m) (FY, 2025) | Net income N/A | Net income ($70.8m) (FY, 2024) | Net income ($92.8m) (FY, 2023) | Net income N/A |
Operating ⚠ | |||||
Patent Applications | Patent Applications 49 (FY, 2017) | Patent Applications N/A | Patent Applications 69 (FY, 2016) | Patent Applications N/A | Patent Applications N/A |
Patents Issued | Patents Issued 104 (FY, 2017) | Patents Issued N/A | Patents Issued 173 (FY, 2016) | Patents Issued N/A | Patents Issued N/A |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round $ 15m (over 9 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 30m (over 6 years ago) |
Total funding raised | Total funding raised $ 103.8m | Total funding raised $ 95.4m | Total funding raised $ 107.5m | Total funding raised N/A | Total funding raised $ 33.4m |
For sources of this data, please see the company profile
View Company Profiles
Metabolon
HQ
Morrisville, US
Employees
191↑ 1% increase
Global leader in metabolomics for precision medicine, biomarker discovery, and advancing pharma & life sciences research.
View companyAdaptimmune
HQ
Philadelphia, US
Employees
400↓ 7% decrease
Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
View companyVBI Vaccines
HQ
Cambridge, US
Employees
123↑ 14% increase
VBI Vaccines is a biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology.
View companyMeissa Vaccines
HQ
South San Francisco, US
Employees
3
Meissa Vaccines is a pharmaceutical company focused on the advancement of unmet vaccines against viruses that cause serious human diseases, such as a respiratory syncytial virus.
View company